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Summary
 
BACKGROUND
 
 
 
AND
 
 
 
OBJECTIVE
 
 
 
The therapeutic effi-
cacy of lanreotide SR and octreotide LAR
 
®
 
 has been
studied widely in patients treated previously with neu-
rosurgery and/or radiotherapy. These therapies limit
the evaluation of the long-term effects of somatostatin
analogues on tumour shrinkage. Neurosurgical and
radiotherapy treatments cause irreversible anatomical
changes in pituitary morphology, which can make accurate
evaluation of tumour shrinkage difficult. The aim of
this study was to investigate the therapeutic efficacy
of lanreotide SR and octreotide LAR
 
®
 
 in previously
untreated patients with acromegaly. We aimed to inves-
tigate the long-term effects of these drugs on tumour
shrinkage and growth hormone (GH) hypersecretion
without the confounding influences of previous therapy.
 
PATIENTS
 
 
 
AND
 
 
 
METHODS
 
 
 
Twenty-three newly diag-
nosed patients with acromegaly (14 women, nine men)
with active disease began the study; of these, three
were lost for follow-up, leaving a total of 20 patients
to complete the study. Patients were assigned ran-
domly to lanreotide SR (12 patients) and octreotide
LAR
 
®
 
 (eight patients), and the randomization stratified
patients to assure a balance between the groups with
respect to baseline tumour dimension, age and sex.
Tumour volume was evaluated by magnetic resonance
imaging of the sella, and calculated with the rotating
ellipsoid formula. A morphological and biochemical
evaluation was performed at baseline, 12 and
24 months after beginning lanreotide SR and octre-
otide LAR
 
®
 
 treatment. A reduction of tumour volume
of at least 10% was considered significant.
 
RESULTS
 
 
 
Biochemical control increased progres-
sively throughout the study in patients with micro-
adenomas more than in patients with macroadenomas
(70% 
 
vs.
 
 10%; 
 
P
 
 < 0·05) and without a difference
between lanreotide SR and octreotide LAR
 
®
 
 (41·0% 
 
vs.
 
37·5%; 
 
P
 
 not significant). After 12 months of treatment,
mean tumour shrinkage was 28·3 
 
– –
––
 
 18·0%. A greater
reduction was observed in macro- 
 
vs
 
.
 
 microadenomas
(40·5 
 
– –
––
 
 17·0% 
 
vs
 
.
 
 16·1 
 
– –
––
 
 8·0%, respectively; 
 
P
 
 
 
< 0·05).
No statistical difference in the tumour shrinking effects
of lanreotide SR 
 
vs
 
.
 
 octreotide LAR
 
®
 
 was observed
(26·5 
 
– –
––
 
 17·3% 
 
vs
 
.
 
 31·1 
 
– –
––
 
 16·1%, respectively). At the
24th month of therapy, no further overall shrinkage
was observed, compared to the 12-month evaluation
(31·9 
 
– –
––
 
 17·2% 
 
vs
 
.
 
 28·3 
 
– –
––
 
 18·0%) at which there was no
difference between lanreotide SR and octreotide LAR
 
®
 
(30·0 
 
– –
––
 
 17·2% 
 
vs
 
.
 
 34·8 
 
– –
––
 
 16·5%, respectively).
 
CONCLUSIONS
 
 
 
This study showed that the new long-
acting somatostatin analogues, lanreotide SR and
octreotide LAR
 
®
 
, cause significant shrinkage of pitu-
itary GH-secreting adenomas in previously untreated
patients with acromegaly. This effect was more marked
in macroadenomas than microadenomas, and did not
correlate with control of GH hypersecretion.
 
In acromegaly, the therapeutic goal is to restore normal growth
hormone (GH) secretory dynamics, normalize serum insulin-like
growth factor-I (IGF-I) levels and shrink the pituitary mass
(Giustina 
 
et al
 
., 2000). Transsphenoidal adenomectomy is con-
sidered the most cost-effective and rapid initial treatment for
acromegalic patients, with a success rate ranging between 48 and
91% (Melmed 
 
et al.
 
, 1998; Freda & Wardlaw, 1999).
Medical therapy has assumed a more prominent role in the
treatment of acromegaly as the number and efficacy of available
therapies have increased (Melmed 
 
et al.
 
, 1998). Octreotide,
administered subcutaneously (s.c.) three times daily, has been
used in the treatment of acromegaly for more than 10 years
(Plewe 
 
et al.
 
, 1984; Ezzat 
 
et al.
 
, 1992; Giustina 
 
et al.
 
, 1996).
Recently, true slow release somatostatin analogues (SMS-a),
such as lanreotide SR, 30 or 60 mg, which can be administered
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intramuscularly (i.m.) every 7–14 days or octreotide LAR
 
®
 
 , 10–
30 mg, given i.m. every 28 days, have been developed (Marek
 
et al.
 
, 1994; Morange 
 
et al.
 
, 1994; Stewart 
 
et al.
 
, 1995; Giusti 
 
et al.
 
,
1996; Lancranjan 
 
et al.
 
, 1996; Caron 
 
et al.
 
, 1997; Flogstad 
 
et al.
 
,
1997; Gillis 
 
et al.
 
, 1997; Davies 
 
et al.
 
, 1998). These drugs
improve compliance and exhibit similar effects on the control of
disease as standard s.c. octreotide therapy.
Recently, the effects of long-acting drugs on GH hypersecre-
tion have been compared and a slightly better effect of octreotide
LAR
 
®
 
 
 
vs.
 
 lanreotide SR in the biochemical control of acromegaly
has been demonstrated (Cozzi 
 
et al.
 
, 1999; Turner 
 
et al.
 
, 1999;
Chanson 
 
et al
 
., 2000). However, in these studies, previous therapies
have limited the evaluation of the long-term therapeutic efficacy
of SMS-a on tumour shrinkage. In fact, previous neurosurgical
and radiotherapy treatments cause irreversible anatomical
changes of pituitary morphology, which can make accurate
evaluation of tumour shrinkage difficult (Barkan 
 
et al.
 
, 1988).
The aim of this study was to investigate the therapeutic efficacy
of lanreotide SR and octreotide LAR
 
®
 
 in previously untreated
patients with acromegaly. We aimed to investigate the long-term
effect of these drugs on tumour shrinkage and GH hypersecretion
without the confounding influences of previous therapy.
 
Patients and methods
 
Twenty-three newly diagnosed patients with acromegaly
(14 women, nine men) with active disease entered the study
(Table 1). Their mean age was 55·0 years (range 40–72). In all
cases the diagnosis was established based on clinical, laboratory
and neuroimaging data (Duncan & Wass, 1999). Thirteen
patients in the study group refused neurosurgery, while 10 were
of high anaesthetic risk due to various systemic diseases (four
patients with cardiac failure, four with chronic obstructive
respiratory disease and two with severe allergy), and therefore
received long-acting SMS-a (lanreotide SR and octreotide LAR
 
®
 
)
treatment as first-line therapy. Patients were randomly assigned
to the two drugs. The computerized randomization stratified
patients to assure balance between the groups with respect to
tumour volume at baseline (micro- and macroadenomas), age and
sex. The study was approved by our Local Ethical Committee,
and all patients gave written informed consent.
Twelve patients received an i.m. injection of lanreotide SR
30 mg (Ipstyl
 
®
 
, Ipsen Biotech Laboratory, Milan, Italy) sequen-
tially every 10 days (Table 1). On the basis of the clinical and
biochemical responses to treatment (target basal GH level, 5 mU/l),
a reduction in the time interval between injections (from 10 to
7 days) was actioned after 3 months. As a result of these dose-
adjustments, five patients remained on 10-day administration and
seven were transfered to a 7-day administration schedule. Eleven
patients underwent therapy with octreotide LAR
 
®
 
 (Sandostatin
 
®
 
LAR
 
®
 
, Novartis Pharma, Basel, Switzerland) at an initial dosage
of 20 mg every 28 days (Table 1). On the basis of the clinical and
biochemical response to treatment (evaluated as above), the dose
was modified (after three administrations) to 30 mg (five patients)
Table 1 Baseline clinical and demographic data of the study population
Patient no. Age Sex Tumoural mass Adenoma volume (ml) GH (mU/l) IGF-I (ng/ml) Drugs Therapeutic regimen
1 40 M Macroadenoma 0·8 76 456·7 LSR 30 mg/7 days
2 40 M Macroadenoma 0·8 70 456·7 OLR 30 mg/28 days
3 59 M Macroadenoma 0·9 72 542·2 OLR 30 mg/28 days
4 56 F Macroadenoma 0·9 112 649·5 LSR 30 mg/7 days
5 56 F Macroadenoma 0·9 114 649·5 LSR 30 mg/7 days
6 44 F Macroadenoma 1·9 70 568·5 LSR 30 mg/7 days
7 47 F Macroadenoma 1·4 66 855·0 OLR 30 mg/28 days
8 59 F Macroadenoma 0·6 40 399·7 LSR 30 mg/7 days
9 68 F Macroadenoma 0·8 36 780·0 OLR 30 mg/28 days
10 72 M Macroadenoma 0·9 80 490·0 LSR 30 mg/10 days
11 66 F Microadenoma 0·3 30 380·0 LSR 30 mg/7 days
12 60 M Microadenoma 0·3 20 720·0 LSR 30 mg/10 days
13 45 F Microadenoma 0·3 52 600·0 LSR 30 mg/7 days
14 40 F Microadenoma 0·2 100 349·5 OLR 20 mg/28 days
15 41 F Microadenoma 0·2 26 348·0 OLR 20 mg/28 days
16 40 M Microadenoma 0·3 38 895·5 LSR 30 mg/10 days
17 50 F Microadenoma 0·2 181 499·5 LSR 30 mg/10 days
18 61 M Microadenoma 0·2 30 411·7 OLR 10 mg/28 days
19 62 F Microadenoma 0·2 16 919·5 OLR 20 mg/28 days
20 59 M Microadenoma 0·5 72 360·0 LSR 30 mg/10 days
LSR, lanreotide SR; OLR, octreotide LAR®.
 
CEN_1438.fm  Page 66  Monday, December 31, 2001  3:53 PM
 Effects of somatostatin analogues in previously untreated acromegaly
 
67
 
© 2002 Blackwell Science Ltd, 
 
Clinical Endocrinology
 
, 
 
56
 
, 65–71
 
or 10 mg (one patient) every 28 days. Three patients receiving
octreotide LAR
 
®
 
  were lost to follow-up (one chose neurosurgery
after the start of medical therapy, two were lost to hospital con-
trol), leaving eight patients for the clinical evaluation (Table 1).
Visual field examination was performed using Goldman
perimetry at baseline and after 12 and 24 months of treatment.
Magnetic resonance imaging (MRI) of the sella, using 0·5 T
 
M
 
r
 
 unit (Vectra, General Electric, Milan, Italy), after intravenous
(i.v.) administration of gadolinium was performed at baseline and
after 12 and 24 months of SMS-a therapy. The tumour size was
evaluated in three dimensions: maximal vertical (V) diameter
was measured on the coronal images, and maximal anteroposte-
rior (AP) and transverse (T) diameters on the axial images. The
volume of the tumour was calculated as the volume of a rotating
ellipsoid, with the following formula: 
 
p
 
/6 (V 
 
·
 
 AP 
 
·
 
 T) (Di
Chiro & Nelson, 1962). All patients had a pituitary adenoma. On
MRI, in particular, a microadenoma (maximal diameter 
 
£
 
 l0 mm)
was observed in 10 patients, and a macroadenoma (maximal
diameter > 10 mm) in the other 10 patients (Table 1). Sixty per
cent of patients with a macroadenoma had a maximal diameter
above 20 mm and in none was it greater than 35 mm. For the
objective assessment, selected hard copy images of pituitary
region were digitized. Pretreatment and post-treatment scans
were evaluated by two radiologists in joint consultations. The
observers were blinded to the dates of the scans. A reduction in
tumour volume of at least 10% was considered significant shrink-
age (Newman 
 
et al.
 
, 1998). Moreover, the degree of shrinkage
was subgrouped into three categories: 10–25% mass reduction,
25–50% and more than 50% shrinkage (Newman 
 
et al.
 
, 1998).
For the purpose of this study, biochemical evaluation of patients
was assessed at baseline (T0), 12 (T12) and 24 (T24) months after
the starting of lanreotide SR and octreotide LAR
 
®
 
  treatment. GH
values were evaluated as the mean of 8-hourly samplings between
08·00 and 15·00 h. Serum GH was measured by an immunora-
diometric assay (Dia Sorin, Saluggia, Italy). The assay sensitivity
was 0·2 mU/l, the intra-assay and interassay coefficients of
variation were 2·1% and 4%, respectively. IGF-I was measured
in fasting blood samples at 08·00 h by immunoradiometric assay
(DSL, Webster, TX, USA). The sensitivity of the assay was
0·8 mg/ml. The intra-assay coefficients of variation were 3·4%,
3·0% and 1·5% for low, medium and high points of the standard
curve, respectively. The interassay coefficients of variation were
8·2%, 1·5% and 3·7% for low, medium and high points of the
standard curve, respectively. The biochemical aimsof treatment
were to obtain serum IGF-I levels in the normal range for sex
and age and a mean of the 8-h GH profile (hourly sampling) less
than 5 mU/l (Orme 
 
et al.
 
, 1998).
 
Statistical analysis
 
Statistical analysis was performed using the SPSS statistical
package. Paired and un-paired data and percentages were com-
pared by 
 
t
 
-test and chi-square test, with Fisher’s correction, when
appropriate. All results are expressed as mean 
 
–
 
 SD. A value of
 
P
 
 < 0·05 was considered significant for all tests.
 
Results
 
At study entry, the mean pituitary adenoma volume for all
patients was 0·63 
 
–
 
 0·47 ml (range 0·18–1·98). Ten patients had
a microadenoma with a mean volume of 0·26 
 
–
 
 0·09 ml (range
0·18–0·50), while the other 10 had a macroadenoma with a mean
volume of 1·00 
 
–
 
 0·40 ml (range 0·61–1·98). While basal GH
values were higher in patients with macroadenomas than micro-
adenomas, no statistical difference in serum IGF1 levels was
observed between the two groups (Table 2). Moreover, at base-
line, no statistical differences were observed between patients
treated with lanreotide SR and octreotide LAR
 
®
 
 for the same
parameters (Table 3).
Only three patients (cases 4, 6 and 7) had modest visual field
abnormalities (quadrantanopia) at baseline.
After 12 months of SMS-a therapy, the mean tumour volume
in all patients was 0·42 
 
–
 
 0·30 ml (range 0·16–1·1), with a mean
reduction of 28·3 
 
–
 
 18·0% (range 4·0–62·5%) with respect to
Table 2 Biochemical and morphological data in patients with macro- and microadenomas: basal and therapeutic responses
Macroadenoma Microadenoma P-value
Basal serum GH levels ( m g/l) 73·6 – 25·0 40·2 – 27·0 < 0·05
Basal IGF-I levels (ng/ml) 584·0 – 148·0 548·4 – 225·0 NS
Patients attaining GH values < 5·0 mU/l at T12 (%) 10·0 60·0 < 0·05
Patients attaining GH values < 5·0 mU/l at T24 (%) 10·0 90·0 < 0·05
Patients attaining normal IGF-I-values at T12 (%) 20·0 70·0 NS
Patients attaining normal IGF-I-values at T24 (%) 40·0 70·0 NS
Shrinkage (% volume reduction) at T12 40·5 – 17·0 16·1 – 8·0 < 0·05
Shrinkage (% volume reduction) at T24 43·7 – 16·8 20·2 – 10 < 0·05
T12, 12th month of therapy; T24, 24th month of therapy. The data are expressed as mean –  SD. NS, not significant.
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basal values. The adenoma shrinkage was 10–25% in 10 cases
(six treated with lanreotide SR, four treated with octreotide LAR
 
®
 
),
25–50% in seven cases (four treated with lanreotide SR, three
treated with octreotide LAR
 
®
 
) and > 50% in two cases (one
treated with lanreotide SR, one treated with octreotide LAR
 
®
 
).
In only one patient (case 20) was no shrinkage was observed.
Tumour shrinkage was greater in macro- than in microadenomas
(40·5 
 
–
 
 17·0% 
 
vs.
 
 16·1 
 
–
 
 8·0%, respectively; 
 
P
 
 < 0·05; Fig. 1a).
In particular, in all patients with microadenomas, the shrinkage
was less than 25%, whereas it was greater than 25% in 9/10
patients with macroadenomas (
 
P 
 
< 0·05; e.g. case 9, Fig. 2).
No statistical difference in tumour shrinkage was observed
between lanreotide SR and octreotide LAR
 
®
 
 (26·5 
 
–
 
 17·3% 
 
vs.
 
31·1 
 
–
 
 16·1%, respectively; Fig. 1b).
A slight improvement in visual fields was found in all three
of the patients who had abnormal findings.
After 12 months of therapy, GH levels below 5 mU/l were
observed in 6/10 patients with a microadenoma and in only one
patient with a macroadenoma (
 
P 
 
< 0·05; Table 2). IGF-I-values
were normalized in 7/10 patients with a microadenoma and in
2/10 patients with a macroadenoma (
 
P
 
 not significant; Table 2).
No statistical difference was observed between the two drugs in
attaining target GH and IGF-I levels (Table 3).
After 24 months of therapy the mean tumour volume in all
patients was 0·39 
 
–
 
 0·25 ml (range 0·14–1·00), with no signific-
ant further shrinkage when compared to the 12-month evalua-
tions (31·9 
 
–
 
 17·2% 
 
vs.
 
 28·3 
 
–
 
 18·0%; 
 
P
 
 not significant; Figs 1a,b
and 2) and with no difference between lanreotide SR and octre-
otide LAR
 
®
 
 (30·0 
 
–
 
 17·2% 
 
vs.
 
 34·8 
 
–
 
 16·5%, respectively; 
 
P
 
 not
significant; Table 3). The percentage of patients with ‘safe’ GH
values and a normal serum IGF-I level for sex and age increased
from 30% (one patient with a macroadenoma, five patients with
microadenomas) to 40% (one patient with a macroadenoma,
seven patients with microadenomas), with no difference between
lanreotide SR and octreotide LAR
 
®
 
 (33·3% 
 
vs.
 
 25·0% at T12 and
41·0% 
 
vs.
 
 37·5% at T24).
 
Discussion
 
This study, performed in previously untreated patients with
acromegaly, showed that long-acting SMS-a induces significant
shrinkage in most patients, particularly those with GH-secreting
macroadenomas. This effect was not correlated with the control
Fig. 1 (a) Shrinkage rates in acromegalic patient with micro- (j) and 
macroadenomas (h). (b) Shrinkage rates in acromegalic patients during 
treatment with lanreotide SR (h) and octreotide LAR® (j).The data are 
expressed as mean –  SD. P < 0·05. T0: before therapy; T12: 12 th month 
of therapy; T24: 24th month of therapy.
Table 3 Biochemical and morphological data in acromegalic patients undergoing treatment with lanreotide SR and octreotide LAR®
Lanreotide SR Octreotide LAR® P-value
Macroadenomas/microadenomas 6/6 4/4 NS
Basal serum GH levels (mU/l) 60·2 – 30·6 52·0 – 31·4 NS
Basal IGF-I levels (ng/ml) 565·7 – 198·7 567·8 – 179·0 NS
Patients attaining GH values < 5·0 mU/l at T12 (%) 33·3 37·5 NS
Patients attaining GH values < 5·0 mU/l at T24 (%) 58·3 50·0 NS
Patients attaining normal IGF-I-values at T12 (%) 50·0 37·5 NS
Patients attaining normal IGF-I-values at T24 (%) 66·7 50·0 NS
Shrinkage (% volume reduction) at T12 26·5 – 17·3 31·1 – 16·1 NS
Shrinkage (% volume reduction) at T24 30·0 – 17·2 34·8 – 16·5 NS
T12, 12th month of therapy; T24, 24th month of therapy. The data are expressed as mean –  SD. NS, not significant.
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of GH hypersecretion which is more evident in patients with
microadenomas.
Transsphenoidal surgery is generally accepted as the initial
therapy for most patients with acromegaly (Freda & Wardlaw,
1999). In this context, medical therapy has been used as an
adjunctive treatment, although the progressive development of
new compounds and easier administration schemes have encour-
aged first-line medical therapy (Ferone et al., 2000). Since most
reports have studied the effects of SMS-a in previously treated
patients with acromegaly, the estimation of the real efficacy of
these drugs on tumour shrinkage has been difficult (Plewe et al.,
1984; Ezzat et al., 1992; Marek et al., 1994; Morange et al.,
1994; Stewart et al., 1995; Giusti et al., 1996; Giustina et al., 1996;
Lancranjan et al., 1996; Caron et al., 1997; Flogstad et al., 1997;
Gillis et al., 1997; Davies et al., 1998; Cozzi et al., 1999; Turner
et al., 1999). In our study, the use of long-acting SMS-a as the
sole treatment tool allowed us to make an accurate estimation of
the long-term hormonal and morphological effects of these drugs.
In the literature, data concerning the effects of lanreotide SR
and octreotide LAR® on tumour shrinkage are scarce, nonhomo-
geneous and difficult to evaluate (Marek et al., 1994; Morange
et al., 1994; Stewart et al., 1995; Giusti et al., 1996; Lancranjan
et al., 1996; Caron et al., 1997; Flogstad et al., 1997; Gillis et al.,
1997; Davies et al., 1998). In fact, transsphenoidal resection
induces anatomical alterations of the pituitary sella, which could
subsequently be modified over subsequent months or years,
causing poor reproducibility of imaging evaluation (Naidich &
Russel, 1999). On the other hand, packing materials placed into
the sella may re-absorb and the volume of the residual mass may
decrease, mimicking a shrinkage effect (Naidich & Russel,
1999). Radiotherapy also modifies pituitary imaging: in fact, it
causes fibreotic changes in the sellar contents, which do not
allow a precise tracing of the tumour margins (Barkan et al.,
1988).
Different criteria have been used to define the tumour mass
before and after therapy in acromegalic patients. In some studies,
a two-dimensional analysis has been performed (Gasperi et al.,
1993; Morange et al., 1994), but with poor accuracy for evalu-
ating small differences of tumour size (Lundin & Pedersen,
1992). In other reports, the parameter of evaluation has not
been specified, making the comparison of results practically
impossible (Marek et al., 1994; Lancranjan et al., 1996; Giusti
et al., 1997). According to previous studies (Arosio et al., 1995;
Caron et al., 1997; Newman et al., 1998), we performed a three-
dimensional analysis which permits a more accurate estimation
of pituitary size for intra- and interpatient comparisons (Lundin
& Pedersen, 1992).
To our knowledge, this is the first study to compare the long-
term effects of lanreotide SR and octreotide LAR® on tumour
shrinkage during a 24-month follow-up period in newly diag-
nosed and previously untreated acromegalic patients. Both the
analogues have shown comparable effects on tumour shrinkage,
which was strictly related to the baseline tumour size. In
particular, clinically significant shrinkage was observed only in
patients with macroadenomas after 1 year of treatment, while
shrinkage was not significant in patients with microadenomas.
The latter patients, however, did not show any increase in tumour
size during the entire study. Clearly, due to the lack of a placebo
control group, we do not know whether pituitary tumour growth
would have occurred in these patients without therapy.
The biochemical control of acromegaly was also different in
patients with micro- and macroadenomas, but in an opposite way
to the tumour shrinkage results. In fact, ‘safe’ GH levels
(£  0.5 mU/l) were obtained in nine of 10 patients with micro-
adenomas, while most patients with macroadenomas did not reach
this therapeutic goal. The different effects of SMS-a on tumour
shrinkage and GH hypersecretion could be explained by the dif-
ferent mechanisms that regulate the antimitotic and antisecretory
Fig. 2 Tumour shrinkage during depot SMS-a therapy. Coronal plane, gadolinium-enhanced T1-weighted MRI scans of a macroadenoma (case 9) at 
the same level through the pituitary fossa before (a) and after 12 (b) and 24 (c) months of lanreotide SR therapy.
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actions of SMS (Lamberts et al., 1996). Indeed, the antisecretory
effects of SMS-a are strictly linked to the reduction of intra-
cellular cyclic AMP concentrations through the inhibition of
adenylate cyclase (Lamberts et al., 1996). On the contrary, the
antimitotic action is related to the stimulation of tyrosine
phosphatase activity, with inhibition of epidermal growth
factor-receptor autophosphorylation, which regulates the cell
proliferation (Lamberts et al., 1996).
Lanreotide SR and octreotide LAR® had a comparable efficacy
on the control of GH hypersecretion, as well as on tumour shrink-
age. While other authors have studied the effects of octreotide
LAR® in patients previously treated by lanreotide SR (Cozzi
et al., 1999; Turner et al., 1999; Chanson et al., 2000), we evalu-
ated the effects of the two drugs on different groups of newly
diagnosed, previously untreated patients. The low number of
enrolled patients permitted us neither to draw definite conclu-
sions concerning the effectiveness of the two long-acting SMS-
a nor to raise objections to the higher effectiveness of octreotide
LAR® with respect to lanreotide SR recently demonstrated in a
multicentre study (Chanson et al., 2000). It is likely that different
dose titrations and frequencies of administration of the two
drugs may be responsible for the different degrees of GH/IGF-
I suppression reported in previous studies (Cozzi et al., 1999;
Turner et al., 1999; Chanson et al., 2000).
The primary goal of therapy is the normalization of serum GH
and IGF-I (Giustina et al., 2000), and tumour shrinkage is a bene-
ficial additional effect of SMS-a, particularly when one is forced
to use primary medical therapy due to patients’ inability/unwill-
ingness to undergo surgery. Therefore our study suggests that,
in patients with macroadenomas, the lack of control of GH hyper-
secretion does not permit the use of SMS-a as a life-long primary
therapy. However, the clearer cut and consistent shrinkage effect
of both lanreotide SR and octreotide LAR® in these patients is
critical in supporting their use before surgical intervention, the
tumour size being one of the main determinants of neurosurgical
failure and the incidence of postsurgery hypopituitarism (Newman
et al., 1998; Laws & Thapar, 1999). Therefore, an increase in
the proportion of surgically controlled patients is likely to be
obtained after tumour mass reduction. We suggest, however, that
preoperative therapy should not last more than 12 months as our
study demonstrated that no further shrinkage occurs after the first
12 months of therapy. In patients with microadenomas, good
control of GH hypersecretion could permit the use of SMS-a for
a longer period without, moreover, the risk of tumour growth. In
these patients, however, medical therapy does not remove the
source of GH hypersecretion and therefore cannot be considered
as the most cost-effective therapeutic tool for every acromegalic
patient with a pituitary microadenoma. In these patients, in fact,
the neurosurgical approach in experienced hands provides up to
a 90% chance of cure (Clayton, 1999). However, those patients
with microadenomas who are unwilling to undergo surgery or
are at very high risk can safely be given a primary long-term
medical regimen with somatostatin analogues.
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